Nepidermin

Summary

Nepidermin is a recombinant analogue of human epidermal growth factor (EGF) investigated as an investigational peptide for promoting tissue repair. It binds the EGF receptor (ErbB1) and activates downstream pathways that stimulate cell proliferation, migration and angiogenesis, making it a candidate for enhancing wound healing and possibly other regenerative applications.

Mechanism of Action

The peptide binds the extracellular domain of the ErbB1 (EGFR) receptor, inducing receptor dimerisation and autophosphorylation of intracellular tyrosine residues. This triggers classic EGFR cascades—including the MAPK/ERK and PI3K/AKT pathways—that drive epithelial and fibroblast proliferation, migration, and new‑blood‑vessel formation. Structural data suggest that under physiological pH the peptide can exist as a dimer, which may influence receptor engagement.

What the Research Shows

Laboratory studies show that synthetic human EGF, the basis of Nepidermin, predominantly forms dimers at pH 7.4 and 37 °C, implicating dimeric forms in receptor interaction (Akunevich et al., 2022). Binding assays in tumor models confirm high affinity for EGFR and illustrate how ligand size affects tissue penetration (Senekowitsch‑Schmidtke, 1999). An alginate‑gum‑arabic hydrogel incorporating an EGF‑derived peptide fragment enhanced fibroblast migration, reduced inflammatory cytokine expression and increased VEGF‑driven angiogenesis in vitro, supporting wound‑repair potential (Keykhaee et al., 2023). A venom‑derived peptide that mimics EGF activates EGFR and provokes prolonged hypersensitivity in mice, underscoring the agonist potency of EGF‑like sequences (Eagles et al., 2022). Reviews describe EGFR transactivation by GPCR‑driven metalloprotease release of endogenous EGF ligands, highlighting broader signalling relevance (Liebmann, 2011). Early recombinant production in E. coli demonstrated biologically active peptide generation (Allen et al., 1985).

Reported Benefits

Pre‑clinical evidence indicates Nepidermin can stimulate fibroblast proliferation and migration, suppress pro‑inflammatory cytokine expression, and up‑regulate angiogenic factors, collectively accelerating wound closure in cell‑based models. Its ability to engage EGFR with high affinity suggests utility in contexts where rapid epithelial regeneration is desired. The peptide’s small size permits topical or intralesional delivery, facilitating localized action.

Limitations of the Evidence

All reported data are limited to in‑vitro experiments, animal models, or biochemical analyses; no human clinical trial results are presented. The propensity of EGF to promote cell proliferation raises theoretical concerns about tumorigenesis, especially given its demonstrated activity in tumor‑bearing models. The physiological relevance of dimeric versus monomeric forms remains unresolved, and optimal dosing, formulation, and long‑term safety have not been established.

Safety Considerations

EGFR activation can drive uncontrolled cell growth, suggesting a potential risk of neoplastic stimulation if used chronically or systemically. The venom‑derived EGF mimic caused prolonged hypersensitivity in mice, indicating that potent EGFR agonism may provoke pain or inflammatory responses. No human adverse‑event data are available, so caution is warranted when considering systemic exposure or use in patients with active malignancies.

How It Is Administered

Investigational studies have employed intralesional injections, subcutaneous administration, and topical formulations, including incorporation into polymeric hydrogels for sustained release. Recombinant production yields a purified peptide suitable for sterile solutions or incorporation into wound‑dressing matrices.

Routes of Administration

Goals & Uses

• Diabetic foot ulcer healingWound HealingModerate
• Post-surgical wound recoveryTissue RepairLow
• Burn wound healingWound HealingModerate
• Chronic wound closureWound HealingModerate
• diabetic foot ulcer closureWound HealingModerate
• Corneal epithelial repairOphthalmologyLow
• burn and skin graft integrationWound HealingLow

Contraindications

• known hypersensitivity to EGF or formulation excipientsAllergyHigh
• Known malignancy at or near application siteOncologyHigh
• Active wound infection (uncontrolled)Infectious DiseaseModerate
• Hypersensitivity to EGF or excipientsAllergy/immunologyHigh
• active malignant disease or proliferative skin lesionsOncologyModerate

Adverse Effects

• pain or burning at application siteSensoryCommon
• Erythema at application siteDermatologicCommon
• PruritusDermatologicUncommonItching
• infection of ulcerInfectiousRare
• Hypersensitivity/allergic reactionImmunologicalRare
• Granuloma formationLocal ReactionRare
• Local erythemaDermatologicCommon
• Local injection site pain/burningLocal ReactionCommon
• Local edemaLocal ReactionUncommon

Drug Interactions

• systemic chemotherapy agentsModerate
• EGFR inhibitors (e.g., erlotinib, cetuximab)High
• other topical growth factorsLow
• Corticosteroids (topical/systemic)Moderate

Population Constraints

• Patients with active malignanciesOncologyAbsolute
• Pediatric patientsAgeRelative
• Pregnant or breastfeeding womenReproductiveRelative
• Immunocompromised patientsImmunologicRelative
• Pregnant womenReproductiveRelative
• Children <12 yearsAgeRelative

Regulatory Status

• European UnionInvestigationalUnder clinical investigation; not authorized for marketing.
• United StatesUnapprovedNot evaluated by FDA; available only in clinical trials.
• United KingdomUnapprovedNo marketing authorization; may be accessed via compassionate use schemes.

Approved in Cuba (Heberprot‑P) for diabetic foot ulcer; not FDA‑approved in the United States and considered investigational in the EU.

Evidence & Sources

• Equilibrium Between Dimeric and Monomeric Forms of Human Epidermal Growth Factor is Shifted Towards Dimers in a Solution
  Journal ArticleLowAkunevich AA, et al.2022-01-01T00:00:00.000000Z
• Binding of EGF peptide and EGF receptor antibodies and its fragments in different tumor models
  Journal ArticleLowSenekowitsch-Schmidtke R1999-01-01T00:00:00.000000Z
• Polysaccharide-based hydrogel enriched by epidermal growth factor peptide fragment for improving the wound healing process
  Journal ArticleLowKeykhaee M, et al.2023-01-01T00:00:00.000000Z
• A peptide toxin in ant venom mimics vertebrate EGF-like hormones to cause long-lasting hypersensitivity in mammals
  Journal ArticleLowEagles DA, et al.2022-01-01T00:00:00.000000Z
• EGF receptor activation by GPCRs: an universal pathway reveals different versions
  Journal ArticleModerateLiebmann C2011-01-01T00:00:00.000000Z
• Production of epidermal growth factor in Escherichia coli from a synthetic gene
  Journal ArticleModerateAllen G, Paynter CA, Winther MD1985-01-01T00:00:00.000000Z

Frequently Asked Questions